A first for New England: Advanced PSMA Prostate Imaging with PET/CT, now available at Shields.
PSMA PET/CT for Reoccurrence (Biochemical failure) – PATIENT CASE STUDY 02
- 68 y/o patient with a history of group grade 3 prostate cancer s/p prostatectomy and now with asymptomatic biochemical failure with PSA or 1.0 ng/ml.
- Negative CT and mpMRI of the pelvis.
Impact of PSMA PET/CT:
- Positive study with nodes outside the pelvis. Risk stratified away from futile salvage radiation therapy.
- Placed on systemic therapy.
Shields PET/CT is proud to lead the way, bringing advanced PSMA imaging to your patients. Our experienced clinical team works with you to improve the treatment, care, and outcomes for intermediate- and high-risk prostate cancer.
For more information about a specific site, please contact 1-800-258-4674.